Sutro Biopharma (NASDAQ:STRO) Posts Earnings Results, Misses Estimates By $2.10 EPS

Sutro Biopharma (NASDAQ:STRO) issued its quarterly earnings data on Thursday. The company reported ($2.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10), RTT News reports. The company had revenue of $14.00 million for the quarter, compared to analyst estimates of $10.44 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same period in the prior year, the company posted ($1.78) EPS.

Sutro Biopharma Trading Down 35.2 %

Shares of STRO stock opened at $0.81 on Friday. The stock has a 50 day moving average of $1.78 and a two-hundred day moving average of $2.78. Sutro Biopharma has a 12 month low of $0.81 and a 12 month high of $6.13. The company has a market capitalization of $66.80 million, a P/E ratio of -0.50 and a beta of 1.22.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on STRO shares. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a report on Monday, November 18th. Bank of America downgraded Sutro Biopharma from a “buy” rating to an “underperform” rating and decreased their target price for the company from $11.00 to $1.00 in a research note on Friday. Citizens Jmp downgraded Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday. Wells Fargo & Company decreased their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Finally, JMP Securities restated a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.00.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.